InvestorsObserver
×
News Home

Should You Buy Imara Inc (IMRA) Stock After it Has Gained 3.70% in a Week?

Tuesday, January 31, 2023 10:03 AM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy Imara Inc (IMRA) Stock After it Has Gained 3.70% in a Week?

The market has been high on Imara Inc (IMRA) stock recently. IMRA gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
Imara Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on IMRA!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With IMRA Stock Today?

Imara Inc (IMRA) stock is down -0.14% while the S&P 500 has risen 0.39% as of 9:39 AM on Tuesday, Jan 31. IMRA is lower by -$0.01 from the previous closing price of $4.50 on volume of 3,786 shares. Over the past year the S&P 500 is lower by -10.68% while IMRA has risen 223.02%. IMRA lost -$1.71 per share in the over the last 12 months.

More About Imara Inc

Imara Inc is a clinical-stage biopharmaceutical company engaged in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Its lead product candidate, tovinontrine (IMR-687), is an oral, highly selective, potent small-molecule inhibitor of phosphodiesterase-9, or PDE9. Click Here to get the full Stock Report for Imara Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App